Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant

• Status: Completed
• Trial end date: 2015-04-01

Summary

Rationale: Giving colony-stimulating factors, such as G-CSF and plerixafor helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored. Purpose: This phase II trial is studying how well plerixafor works in patients with multiple myeloma previously treated with lenalidomide and planning to undergo autologous stem cell transplant.

• Phase: Phase 2

Details

• Lead Sponsor: Mayo Clinic
• Treatments: JM 3100; Lenalidomide; Lenograstim; Plerixafor; Sargramostim